W
Wenlin Shao
Researcher at Novartis
Publications - 36
Citations - 3543
Wenlin Shao is an academic researcher from Novartis. The author has contributed to research in topics: Panobinostat & Cancer. The author has an hindex of 16, co-authored 33 publications receiving 3204 citations.
Papers
More filters
Journal ArticleDOI
Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling
Shih Min A Huang,Yuji Mishina,Shanming Liu,Atwood K. Cheung,Frank Stegmeier,Gregory A. Michaud,Olga Charlat,Elizabeth Wiellette,Yue Zhang,Stephanie Wiessner,Marc Hild,Xiaoying Shi,Christine D. Wilson,Craig Mickanin,Vic E. Myer,Aleem Fazal,Ronald Tomlinson,Fabrizio C. Serluca,Wenlin Shao,Hong Cheng,Michael Shultz,Christina Rau,Markus Schirle,Judith Schlegl,Sonja Ghidelli,Stephen Fawell,Chris Lu,Daniel Curtis,Marc W. Kirschner,Christoph Lengauer,Peter Finan,John A. Tallarico,Tewis Bouwmeester,Jeffery A. Porter,Andreas Bauer,Feng Cong +35 more
TL;DR: This study uses a chemical genetic screen to identify a small molecule, XAV939, which selectively inhibits β-catenin-mediated transcription and reveals new mechanistic insights into the regulation of axin protein homeostasis, which presents new avenues for targeted Wnt pathway therapies.
Journal ArticleDOI
Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A - TCF7L2 fusion
Adam J. Bass,Adam J. Bass,Michael S. Lawrence,Lear E. Brace,Alex H. Ramos,Alex H. Ramos,Yotam Drier,Kristian Cibulskis,Carrie Sougnez,Douglas Voet,Gordon Saksena,Andrey Sivachenko,Rui Jing,Melissa Parkin,Trevor J. Pugh,Trevor J. Pugh,Roel G.W. Verhaak,Nicolas Stransky,Adam T. Boutin,Jordi Barretina,David B. Solit,Evi Vakiani,Wenlin Shao,Yuji Mishina,Markus Warmuth,Jose Jimenez,Derek Y. Chiang,Sabina Signoretti,William G. Kaelin,Nicole Spardy,William C. Hahn,William C. Hahn,Yujin Hoshida,Shuji Ogino,Ronald A. DePinho,Lynda Chin,Levi A. Garraway,Levi A. Garraway,Charles S. Fuchs,Jose Baselga,Jose Baselga,Josep Tabernero,Stacey Gabriel,Eric S. Lander,Eric S. Lander,Gad Getz,Matthew Meyerson,Matthew Meyerson +47 more
TL;DR: Previously unidentified levels of genomic rearrangements in colorectal carcinoma that can lead to essential gene fusions and other oncogenic events are shown.
Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion
Adam J. Bass,Adam J. Bass,Michael S. Lawrence,Lear E. Brace,Alex H. Ramos,Alex H. Ramos,Yotam Drier,Kristian Cibulskis,Carrie Sougnez,Douglas Voet,Gordon Saksena,Andrey Sivachenko,Rui Jing,Melissa Parkin,Trevor J. Pugh,Trevor J. Pugh,Roel G.W. Verhaak,Nicolas Stransky,Adam T. Boutin,Jordi Barretina,David B. Solit,Evi Vakiani,Wenlin Shao,Yuji Mishina,Markus Warmuth,Jose Jimenez,Derek Y. Chiang,Sabina Signoretti,William G. Kaelin,Nicole Spardy,William C. Hahn,William C. Hahn,Yujin Hoshida,Shuji Ogino,Ronald A. DePinho,Lynda Chin,Levi A. Garraway,Levi A. Garraway,Charles S. Fuchs,Jose Baselga,Jose Baselga,Josep Tabernero,Stacey Gabriel,Eric S. Lander,Eric S. Lander,Gad Getz,Matthew Meyerson,Matthew Meyerson +47 more
TL;DR: In this paper, the authors identify an average of 75 somatic rearrangements per tumor, including complex networks of translocations between pairs of chromosomes, which can lead to essential gene fusions and other oncogenic events.
Journal ArticleDOI
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure
TL;DR: Clinical evidence supporting oncogene addiction is described and common mechanistic themes emerging from the response and acquired resistance to oncogen‐targeted therapies are discussed, suggesting several opportunities toward exploiting oncogenic addiction to achieve curative cancer therapies.
Journal ArticleDOI
In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma
Enrique M. Ocio,David Vilanova,Peter Atadja,Patricia Maiso,Edvan de Queiroz Crusoe,Diego Fernández-Lázaro,Mercedes Garayoa,Laura San-Segundo,Teresa Hernández-Iglesias,Enrique de Alava,Wenlin Shao,Yung-mae Yao,Atanasio Pandiella,Jesús F. San-Miguel +13 more
TL;DR: The addition of panobinostat to dexamethasone and either bortezomib or lenalidomide plus steroids resulted in clear potentiation in multiple myeloma cell lines, freshly isolated plasma cells, and murine models of multipleMyeloma.